Creating a new drug to treat heart damage after a heart attack
Developing a new drug for treating myocardial ischemia/reperfusion injury
This study is testing a new medication that aims to help people who have had a heart attack by reducing heart damage when blood flow is restored, and it could lead to better recovery and lower chances of heart failure.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dupage Medical Technology, INC. NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10491205 on NIH RePORTER |
What this research studies
This research focuses on developing a new medication aimed at reducing heart damage caused by myocardial ischemia/reperfusion injury, which occurs when blood flow is restored to the heart after a blockage. The approach involves understanding the role of inflammation and microvascular thrombosis in this injury, and how existing anti-platelet drugs can be optimized for better outcomes. Patients who have experienced a heart attack may benefit from this new treatment, which seeks to improve recovery and reduce the risk of heart failure. The research will involve clinical trials to assess the effectiveness and safety of the new drug.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have recently suffered a myocardial infarction and are at risk of subsequent heart failure.
Not a fit: Patients who have not experienced a heart attack or those with advanced heart failure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly reduces heart damage and improves recovery for heart attack survivors.
How similar studies have performed: Previous research has shown promise in using anti-platelet therapies for myocardial infarction, but this approach aims to refine and enhance those treatments for better outcomes.
Where this research is happening
Chicago, UNITED STATES
- Dupage Medical Technology, INC. — Chicago, United States (Active)
Researchers
- Principal investigator: Skidgel, Randal a — Dupage Medical Technology, INC.
- Study coordinator: Skidgel, Randal a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.